血浆肉碱水平与阿尔茨海默病的相关性研究

The study of the relation of the blood plasma carnitine level and Alzheimer disease

目的探讨血浆肉碱缺乏是否是阿尔茨海默病(AD)和轻度认知功能障碍(MCI)的危险因素,评价左旋肉碱(商品名:东维力)治疗AD与MCI的疗效。方法对80例AD和80例MCI患者随机双盲分组为治疗组和对照组,治疗组给予左旋肉碱加阿司匹林和尼莫地平片口服,对照组给予阿司匹林和尼莫地平片口服,12周为1个疗程。治疗前后分别测定简易智能精神状态检查量表(MMSE),日常生活能力量表(ADL)和临床痴呆程度量表(CDR),治疗前后分别测定游离肉碱含量。结果与对照组比较,治疗组的MMSE、ADL、CDR评分在治疗后均有显著改善(P<0.05)。AD与MCI患者治疗前血浆肉碱水平均明显低于正常,治疗组和对照组的血浆左旋肉碱水平相比较差异无统计学意义(P>0.05)。治疗组在治疗36周后血浆肉碱水平较对照组明显升高(P<0.05)。结论血浆肉碱缺乏是AD与MCI的危险因素,血浆肉碱是AD与MCI的生物标记物;左旋肉碱可改善AD与MCI患者的认知功能,痴呆程度和日常生活自理能力,是AD与MCI治疗的有效药物之一。

Objective To evaluate whether the insufficiency of the blood plasma carnitine is the dangerous risk factor of the Alzheimer disease （AD） and mild cognitive impairment （MCI）. And to assess therapeutic effect of the levo -earnitine on the Alzheimer disease and patients with mild cognitive impairment. Methods 80 AD and 80 MCI patients were double blind divided into experimental group and control group. MMSE, ADL and CDR were used to evaluate the therapeutic effect of the levo - earnitine. Results Compared with the control group, the scores of the MMSE, ADL and CDR of experimental group improved significantly （ P 〈 0.05 ）. There were no significant difference between the experimental group and the controls （ P 〉 0.05 ）. After treating for 36 weeks, the blood plasma carni tine was significantly increased in the experimental group （ P 〈 0.05 ）. Conclusion The insufficiency of the blood plasma earnitine is the dangerous risk factor in AD and MCI patients. The blood plasma carnitine is the biological tag of AD/MCI, levo carnitine can iraprove cognitive function, dementia and self care ability, and levo carnitine is one of the effective medicines to treat AD/MCI.